Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to ... PharmaLive (press release) (subscription) In addition, Proteo's licensing and development partner, Minapharm Pharmaceuticals SAE, has initiated a Phase II clinical trial on the use of Elafin for kidney transplantation patients. This trial is concerned with the prevention of acute organ ... |
